Modest rescue of RBFOX1 splicing function attenuates Huntington's disease features.

Overview

1. Center for Molecular Biology Severo Ochoa (CBM Severo Ochoa) CSIC/UAM, C/ Nicolás Cabrera, 1, Madrid, 28049 Spain
2. Networking Biomedicine Research Center on Neurodegenerative Diseases (CIBER-NED), Instituto de Salud Carlos III,Madrid, 28031 Spain

Abstract

Background: RNA mis-splicing underlies a growing number of neurological disorders and, consequently, splicing correction therapies have been developed for some monogenic forms, like spinal muscular atrophy or neuronal ceroid lipofuscinosis. In Huntington’s disease (HD), alternative splicing alteration emerged as a molecular mechanism in view of individually reported mis-splicing events in neurodegeneration-linked genes such as HTT itself, MAPT and TAF1. Later, more systematic genome-wide RNA-seq analyses of HD brains revealed mis-splicing signatures involving additional neurodegeneration-linked genes. Individual correction of each of the potentially pathogenic mis-spliced genes would be unapproachable. However, the identification of upstream pivotal splicing factors altered in HD may be useful to design pleiotropic therapeutic strategies. We previously performed motif-enrichment analyses of the sequences flanking exons that are mis-spliced in HD and identified RBFOX splicing factors as underlying candidates.

Methods: We performed RT-PCR and Western blot analyses of RBFOX in post-mortem brain samples from HD patients and mice. We generated transgenic mouse lines overexpressing RBFOX1 in forebrain neurons and performed RNA-seq to analyze its impact on HD-associated mis-splicing. In addition, we combined HD mice with RBFOX1-overexpressing mice to verify correction of Rbfox1 levels and mis-splicing of RBFOX target genes, and performed histopathological and motor behavioral analyses.

Results: We observed that decreased expression of Rbfox1 in striatum of HD mice at early stages of disease progression correlates with a reduction of Rbfox1 immunostaining particularly in the nucleus. This prompted us to generate transgenic mouse lines overexpressing the nuclear isoform of RBFOX1. The overexpression of RBFOX1 in this new transgenic mouse line induced widespread alternative splicing changes that significantly overlapped with genes mis-spliced in brains of both HD patients and mouse models. We found that moderate neuronal RBFOX1 overexpression in HD mice results in correction of several HD-associated mis-splicing events and in attenuation of neurodegeneration and motor symptoms.

Conclusions: These results demonstrate that the observed decrease of RBFOX1 levels in brains of HD patients and mice contributes to HD pathogenesis and suggest therapeutic potential of RBFOX-increasing strategies for HD.

Supplementary Information: The online version contains supplementary material available at 10.1186/s10020-026-01471-y.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• figshare:31986374, at figshare; found in DataCite
• figshare:31986377, at figshare; found in DataCite
• figshare:31986380, at figshare; found in DataCite

Data availability

Data generated in this study are available from the corresponding author upon reasonable request. The RNA-seq dataset will be available at the European Nucleotide Archive (ENA) database with accession number PRJEB110930.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 6 authors, 5 keywords, 13 MeSH terms, 1 funder, 50 references.

Cite

This paper

Lozano-Muñoz, D., Elorza, A., Lucas-Santamaría, M., Santos-Galindo, M., Parras, A., & Lucas, J. J. (2026). Modest rescue of RBFOX1 splicing function attenuates Huntington's disease features. Molecular medicine (Cambridge, Mass.), 32(1), 56. https://doi.org/10.1186/s10020-026-01471-y

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s11658-026-00948-2 [code]

Phosphoproteomic profiling reveals post-translational dysregulation in Huntington's disease patient-derived neurons.

Journal: Cellular & molecular biology letters

In common: other condition, 5 references

[2] doi:10.1242/dmm.052803

Molecular features of a Huntington's disease knock-in minipig.

Journal: Disease models & mechanisms

In common: other condition, 3 references

[3] doi:10.1523/jneurosci.0019-26.2026 [code]

Endothelial <i>Adgrl2</i> Expression and Alternative Splicing Controls the Cerebrovasculature.

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience

In common: mouse, 3 references

[4] doi:10.1186/s13024-026-00960-2 [code]

Temporal single-cell atlas of full-length Huntington's disease mouse model defines stage-specific signatures of corticostriatal dysfunction.

Journal: Molecular neurodegeneration

In common: other condition, mouse, 2 references

[5] doi:10.1038/s41586-026-10671-9 [code]

Restoring cortical disinhibition improves Huntington's disease phenotypes.

Journal: Nature

In common: other condition, mouse, 2 references

[6] doi:10.1093/nar/gkag451 [code]

An in vivo parallelized reporter assay to uncover tissue-specific splicing regulatory sequences in a multicellular animal.

Journal: Nucleic acids research

In common: 2 references

[7] doi:10.1038/s44321-026-00459-9

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.

Journal: EMBO molecular medicine

In common: other condition, mouse, 2 references

[8] doi:10.1016/j.nbd.2026.107475

Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient mice.

Journal: Neurobiology of disease

In common: mouse, 2 references

[9] doi:10.1093/brain/awag028

Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington's disease.

Journal: Brain : a journal of neurology

In common: other condition, mouse, 1 reference

[10] doi:10.1242/jcs.264353

Alternatively spliced STIM2.3 is an evolutionarily late store-operated Ca2+ entry regulator expressed in brain.

Journal: Journal of cell science

In common: histology / microscopy, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.